<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>2604-7306</journal-id>
<journal-title><![CDATA[REC: Interventional Cardiology]]></journal-title>
<abbrev-journal-title><![CDATA[REC Interv Cardiol ES]]></abbrev-journal-title>
<issn>2604-7306</issn>
<publisher>
<publisher-name><![CDATA[Sociedad Española de Cardiología]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S2604-73062025000400206</article-id>
<article-id pub-id-type="doi">10.24875/recic.m25000524</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Serie de casos de implante de prótesis percutánea tricúspide EVOQUE en España: experiencia clínica y resultados iniciales]]></article-title>
<article-title xml:lang="en"><![CDATA[Case series of transcatheter tricuspid EVOQUE valve implantation in Spain: clinical experience and early outcomes]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sanz]]></surname>
<given-names><![CDATA[Ana Pardo]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Tahoces]]></surname>
<given-names><![CDATA[Luisa Salido]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martín]]></surname>
<given-names><![CDATA[Ana García]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[Ariana González]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Rodríguez]]></surname>
<given-names><![CDATA[Luis Manuel Domínguez]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Casanova]]></surname>
<given-names><![CDATA[José Alfredo Salinas]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lobán]]></surname>
<given-names><![CDATA[Covadonga Fernández-Golfín]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[José Luis Zamorano]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
<xref ref-type="aff" rid="A a"/>
<xref ref-type="aff" rid="A3"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sánchez-Recalde]]></surname>
<given-names><![CDATA[Ángel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
<xref ref-type="aff" rid="Aaf"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital Universitario Ramón y Cajal Servicio de Cardiología ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS) ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Instituto de Salud Carlos III Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV) ]]></institution>
<addr-line><![CDATA[Madrid ]]></addr-line>
<country>Spain</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2025</year>
</pub-date>
<volume>7</volume>
<numero>4</numero>
<fpage>206</fpage>
<lpage>212</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S2604-73062025000400206&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S2604-73062025000400206&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S2604-73062025000400206&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN  Introducción y objetivos: El tratamiento percutáneo de la insuficiencia tricuspídea (IT) ha supuesto una revolución en el abordaje de estos pacientes en los últimos años. El sistema EVOQUE (Edwards Lifesciences, EE.UU.), que obtuvo el marcado CE 2023, es una prótesis tricúspide percutánea diseñada para tratar casos de IT grave que no son reparables mediante otras técnicas percutáneas. Este trabajo presenta la experiencia inicial en nuestro centro con el implante de prótesis EVOQUE en 10 pacientes con IT sintomática. Nuestro objetivo fue analizar el seguimiento inicial a 30 días, clínico y por imagen.  Métodos: Estudio observacional prospectivo unicéntrico. Se incluyeron 10 pacientes seleccionados con IT grave a los que se implantó una prótesis EVOQUE. La evolución clínica inicial se evaluó mediante parámetros clínicos y ecocardiográficos a los 30 días. Se valoraron la reducción de la IT, la función ventricular derecha y las posibles complicaciones posoperatorias.  Resultados: Se incluyeron 10 pacientes con IT grave sintomática. La mediana de seguimiento fue de 80 días y la edad media de los pacientes fue de 77,2 años; TRISCORE medio 4,6; EuroSCORE II medio 3,9%. Un 40% de los pacientes eran portadores de marcapasos. El éxito del procedimiento fue del 100% según los criterios del Tricuspid Valve Academic Research Consortium. Se produjo una reducción marcada de la IT en todos los casos, quedando IT leve o mínima tras el procedimiento. El gradiente transprotésico medio fue de 2,5 mmHg. Como complicaciones destacaron 1 caso de insuficiencia mitral grave posimplante, 1 bloqueo auriculoventricular completo, 2 fallos ventriculares derechos transitorios y 2 trombosis de prótesis. La mediana de estancia hospitalaria fue de 7 días.  Conclusiones: El implante de prótesis tricúspide EVOQUE ofrece resultados iniciales prometedores, con una reducción prácticamente completa de la IT y pocas complicaciones. Son necesarios más estudios para confirmar la seguridad y eficacia del dispositivo en la práctica clínica.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  Introduction and objectives: Transcatheter treatment for tricuspid regurgitation (TR) has grown exponentially in recent years. The Edwards EVOQUE system (Edwards Lifesciences, United States), which obtained CE marking in 2023, is a transcatheter tricuspid valve designed to address severe cases of TR that are not amenable to repair using other transcatheter techniques. This study presents the initial experience at our center with the implantation of the EVOQUE tricuspid valve in 10 patients with symptomatic TR. Our objective was to analyze the initial clinical and 30-day imaging follow-up.  Methods: We conducted a prospective, single-center observational study. A total of 10 patients with severe TR who underwent EVOQUE tricuspid valve implantation were included. The 30-day early outcomes were evaluated using clinical parameters and echocardiographic findings. We assessed the reduction of TR, right ventricular function, and potential postoperative complications.  Results: Ten patients with symptomatic severe TR were included. The median follow-up was 80 days, and the patients&#8217; mean age, 77.2 years. The mean TRISCORE was 4.6, and the mean EuroSCORE II, 3.9%. Pacemaker dependance was observed in 40% of patients. The rate of procedural success was 100% according to the Tricuspid Valve Academic Research Consortium criteria. The maximum transprosthetic gradient was 4.8 mmHg. Significant complications included 1 case of severe mitral regurgitation following implantation, 1 complete atrioventricular block, 2 transient right ventricular failures, and 2 prosthetic valve thromboses. The median length of stay was 7 days.  Conclusions: The early outcomes of the EVOQUE tricuspid valve implantation are promising, with significant TR reduction and few complications. Further studies are needed to confirm the safety and efficacy profile of the device in the routine clinical practice.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Insuficiencia tricuspídea]]></kwd>
<kwd lng="es"><![CDATA[Prótesis EVOQUE]]></kwd>
<kwd lng="es"><![CDATA[Implante percutáneo]]></kwd>
<kwd lng="es"><![CDATA[Fallo ventricular derecho]]></kwd>
<kwd lng="es"><![CDATA[Bloqueo auriculoventricular]]></kwd>
<kwd lng="es"><![CDATA[Trombosis de prótesis]]></kwd>
<kwd lng="en"><![CDATA[Tricuspid regurgitation]]></kwd>
<kwd lng="en"><![CDATA[EVOQUE tricuspid valve]]></kwd>
<kwd lng="en"><![CDATA[Transcatheter implantation]]></kwd>
<kwd lng="en"><![CDATA[Right ventricular failure]]></kwd>
<kwd lng="en"><![CDATA[Atrioventricular block]]></kwd>
<kwd lng="en"><![CDATA[Prosthetic valve thrombosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nishiura]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Kitai]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Okada]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-Term Clinical Outcomes in Patients With Severe Tricuspid Regurgitation]]></article-title>
<source><![CDATA[J Am Heart Assoc]]></source>
<year>2023</year>
<volume>12</volume>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Messika-Zeitoun]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Chan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Labinaz]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Burwash]]></surname>
<given-names><![CDATA[IG]]></given-names>
</name>
<name>
<surname><![CDATA[Dreyfus]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Intervention for Tricuspid Valve Regurgitation:Timing Is Key, and Earlier Is Better Than Later]]></article-title>
<source><![CDATA[Can J Cardiol]]></source>
<year>2024</year>
<volume>40</volume>
<page-range>182-4</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Scotti]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Sturla]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Granada]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Outcomes of isolated tricuspid valve replacement:a systematic review and meta-analysis of 5,316 patients from 35 studies]]></article-title>
<source><![CDATA[EuroIntervention]]></source>
<year>2022</year>
<volume>18</volume>
<page-range>840-51</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Vahanian]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Beyersdorf]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Praz]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[2021 ESC/EACTS Guidelines for the management of valvular heart disease:Developed by the Task Force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2022</year>
<volume>43</volume>
<page-range>561-632</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nickenig]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Kowalski]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Hausleiter]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transcatheter Treatment of Severe Tricuspid Regurgitation With the Edge-to-Edge MitraClip Technique]]></article-title>
<source><![CDATA[Circulation]]></source>
<year>2017</year>
<volume>135</volume>
<page-range>1802-14</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pardo]]></surname>
<given-names><![CDATA[Sanz A]]></given-names>
</name>
<name>
<surname><![CDATA[Gómez]]></surname>
<given-names><![CDATA[JLZ]]></given-names>
</name>
<name>
<surname><![CDATA[Tahoces]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Long-term outcomes of percutaneous tricuspid annuloplasty with Cardioband device]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Imaging]]></source>
<year>2022</year>
<volume>23</volume>
<page-range>979-88</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Zamorano]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The need for a new tricuspid regurgitation grading scheme]]></article-title>
<source><![CDATA[Eur Heart J Cardiovasc Imaging]]></source>
<year>2017</year>
<volume>18</volume>
<page-range>1342-3</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Li]]></surname>
<given-names><![CDATA[C-HP]]></given-names>
</name>
<name>
<surname><![CDATA[Asmarats]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Santaló-Corcoy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Initial experience on percutaneous tricuspid valve replacement using the EVOQUE prosthesis]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2025</year>
<volume>78</volume>
<page-range>74-5</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Makkar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Makar]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[EVOQUE Tricuspid Valve Replacement System:State-of-the-Art Screening and Intraprocedural Guidance]]></article-title>
<source><![CDATA[JACC Cardiovasc Interv]]></source>
<year>2024</year>
<volume>17</volume>
<page-range>2093-112</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[González-Gómez]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fernández-Golfín]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hinojar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The 4A classification for patients with tricuspid regurgitation]]></article-title>
<source><![CDATA[Rev Esp Cardiol]]></source>
<year>2023</year>
<volume>76</volume>
<page-range>845-51</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Lawlor]]></surname>
<given-names><![CDATA[MK]]></given-names>
</name>
<name>
<surname><![CDATA[Davidson]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Tricuspid Valve Academic Research Consortium Definitions for Tricuspid Regurgitation and Trial Endpoints]]></article-title>
<source><![CDATA[Ann Thorac Surg]]></source>
<year>2023</year>
<volume>116</volume>
<page-range>908-32</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kodali]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Makkar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transfemoral tricuspid valve replacement and one-year outcomes:the TRISCEND study]]></article-title>
<source><![CDATA[Eur Heart J]]></source>
<year>2023</year>
<volume>44</volume>
<page-range>4862-73</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
<name>
<surname><![CDATA[Makkar]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Thourani]]></surname>
<given-names><![CDATA[VH]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Transcatheter Valve Replacement in Severe Tricuspid Regurgitation]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2025</year>
<volume>392</volume>
<page-range>115-26</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Grayburn]]></surname>
<given-names><![CDATA[PA]]></given-names>
</name>
<name>
<surname><![CDATA[Kodali]]></surname>
<given-names><![CDATA[SK]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[RT]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[TRISCEND II:Novel Randomized Trial Design for Transcatheter Tricuspid Valve Replacement]]></article-title>
<source><![CDATA[Am J Cardiol]]></source>
<year>2024</year>
<volume>225</volume>
<page-range>171-7</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
